返回新闻

新闻来自 Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited
#Pharma #Healthcare
31 October 2022

Grand Pharma’s Global Innovative Product STC3141 Achieved the Clinical Endpoint of The Phase Ib Clinical Trial for the Treatment of ARDS in China

Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited
#Pharma #Business & Finance
11 August 2022

Constantly Strategical Planning High-Growth Sectors, Grand Pharma’s 2022 Interim Results Continue to Grow

Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited
#Pharma #Finance
08 August 2022

Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on High-quality Amino Acid Industry

立即联系 Media OutReach

立即联系我们